The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity

M.A Albrecht, G. Roberts, Gregory Price, Joseph Lee, R. Iyyalol, Mathew Martin-Iverson

    Research output: Contribution to journalArticle

    7 Citations (Scopus)
    511 Downloads (Pure)

    Abstract

    © 2015 Wiley Periodicals, Inc. The catecholamines—dopamine and noradrenaline—play important roles in directing and guiding behavior. Disorders of these systems, particularly within the dopamine system, are associated with several severe and chronically disabling psychiatric and neurological disorders. We used the recently published group independent components analysis (ICA) procedure outlined by Chen et al. (2013) to present the first pharmaco-EEG ICA analysis of the resting-state EEG in healthy participants administered 0.45 mg/kg dexamphetamine. Twenty-eight healthy participants between 18 and 41 were recruited. Bayesian nested-domain models that explicitly account for spatial and functional relationships were used to contrast placebo and dexamphetamine on component spectral power and several connectivity metrics. Dexamphetamine led to reductions across delta, theta, and alpha spectral power bands that were predominantly localized to Frontal and Central regions. Beta 1 and beta 2 power were reduced by dexamphetamine at Frontal ICs, while beta 2 and gamma power was enhanced by dexamphetamine in posterior regions, including the parietal, occipital-temporal, and occipital regions. Power–power coupling under dexamphetamine was similar for both states, resembling the eyes open condition under placebo. However, orthogonalized measures of power coupling and phase coupling did not show the same effect of dexamphetamine as power-power coupling. We discuss the alterations of low- and high-frequency EEG power in response to dexamphetamine within the context of disorders of dopamine regulation, in particular schizophrenia, as well as in the context of a recently hypothesized association between low-frequency power and aspects of anhedonia. Hum Brain Mapp 37:570–588, 2016.
    Original languageEnglish
    Pages (from-to)570–588
    Number of pages19
    JournalHuman Brain Mapping
    Volume37
    Issue number2
    DOIs
    Publication statusPublished - Feb 2016

    Fingerprint

    Dextroamphetamine
    Electroencephalography
    Dopamine
    Healthy Volunteers
    Placebos
    Anhedonia
    Power (Psychology)
    Occipital Lobe
    Parietal Lobe
    Temporal Lobe
    Nervous System Diseases
    Psychiatry
    Schizophrenia

    Cite this

    @article{731b33a8df1345eb88315c94c814eb18,
    title = "The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity",
    abstract = "{\circledC} 2015 Wiley Periodicals, Inc. The catecholamines—dopamine and noradrenaline—play important roles in directing and guiding behavior. Disorders of these systems, particularly within the dopamine system, are associated with several severe and chronically disabling psychiatric and neurological disorders. We used the recently published group independent components analysis (ICA) procedure outlined by Chen et al. (2013) to present the first pharmaco-EEG ICA analysis of the resting-state EEG in healthy participants administered 0.45 mg/kg dexamphetamine. Twenty-eight healthy participants between 18 and 41 were recruited. Bayesian nested-domain models that explicitly account for spatial and functional relationships were used to contrast placebo and dexamphetamine on component spectral power and several connectivity metrics. Dexamphetamine led to reductions across delta, theta, and alpha spectral power bands that were predominantly localized to Frontal and Central regions. Beta 1 and beta 2 power were reduced by dexamphetamine at Frontal ICs, while beta 2 and gamma power was enhanced by dexamphetamine in posterior regions, including the parietal, occipital-temporal, and occipital regions. Power–power coupling under dexamphetamine was similar for both states, resembling the eyes open condition under placebo. However, orthogonalized measures of power coupling and phase coupling did not show the same effect of dexamphetamine as power-power coupling. We discuss the alterations of low- and high-frequency EEG power in response to dexamphetamine within the context of disorders of dopamine regulation, in particular schizophrenia, as well as in the context of a recently hypothesized association between low-frequency power and aspects of anhedonia. Hum Brain Mapp 37:570–588, 2016.",
    author = "M.A Albrecht and G. Roberts and Gregory Price and Joseph Lee and R. Iyyalol and Mathew Martin-Iverson",
    year = "2016",
    month = "2",
    doi = "10.1002/hbm.23052",
    language = "English",
    volume = "37",
    pages = "570–588",
    journal = "Human Brain Mapping",
    issn = "1065-9471",
    publisher = "Wiley-Liss",
    number = "2",

    }

    The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity. / Albrecht, M.A; Roberts, G.; Price, Gregory; Lee, Joseph; Iyyalol, R.; Martin-Iverson, Mathew.

    In: Human Brain Mapping, Vol. 37, No. 2, 02.2016, p. 570–588.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity

    AU - Albrecht, M.A

    AU - Roberts, G.

    AU - Price, Gregory

    AU - Lee, Joseph

    AU - Iyyalol, R.

    AU - Martin-Iverson, Mathew

    PY - 2016/2

    Y1 - 2016/2

    N2 - © 2015 Wiley Periodicals, Inc. The catecholamines—dopamine and noradrenaline—play important roles in directing and guiding behavior. Disorders of these systems, particularly within the dopamine system, are associated with several severe and chronically disabling psychiatric and neurological disorders. We used the recently published group independent components analysis (ICA) procedure outlined by Chen et al. (2013) to present the first pharmaco-EEG ICA analysis of the resting-state EEG in healthy participants administered 0.45 mg/kg dexamphetamine. Twenty-eight healthy participants between 18 and 41 were recruited. Bayesian nested-domain models that explicitly account for spatial and functional relationships were used to contrast placebo and dexamphetamine on component spectral power and several connectivity metrics. Dexamphetamine led to reductions across delta, theta, and alpha spectral power bands that were predominantly localized to Frontal and Central regions. Beta 1 and beta 2 power were reduced by dexamphetamine at Frontal ICs, while beta 2 and gamma power was enhanced by dexamphetamine in posterior regions, including the parietal, occipital-temporal, and occipital regions. Power–power coupling under dexamphetamine was similar for both states, resembling the eyes open condition under placebo. However, orthogonalized measures of power coupling and phase coupling did not show the same effect of dexamphetamine as power-power coupling. We discuss the alterations of low- and high-frequency EEG power in response to dexamphetamine within the context of disorders of dopamine regulation, in particular schizophrenia, as well as in the context of a recently hypothesized association between low-frequency power and aspects of anhedonia. Hum Brain Mapp 37:570–588, 2016.

    AB - © 2015 Wiley Periodicals, Inc. The catecholamines—dopamine and noradrenaline—play important roles in directing and guiding behavior. Disorders of these systems, particularly within the dopamine system, are associated with several severe and chronically disabling psychiatric and neurological disorders. We used the recently published group independent components analysis (ICA) procedure outlined by Chen et al. (2013) to present the first pharmaco-EEG ICA analysis of the resting-state EEG in healthy participants administered 0.45 mg/kg dexamphetamine. Twenty-eight healthy participants between 18 and 41 were recruited. Bayesian nested-domain models that explicitly account for spatial and functional relationships were used to contrast placebo and dexamphetamine on component spectral power and several connectivity metrics. Dexamphetamine led to reductions across delta, theta, and alpha spectral power bands that were predominantly localized to Frontal and Central regions. Beta 1 and beta 2 power were reduced by dexamphetamine at Frontal ICs, while beta 2 and gamma power was enhanced by dexamphetamine in posterior regions, including the parietal, occipital-temporal, and occipital regions. Power–power coupling under dexamphetamine was similar for both states, resembling the eyes open condition under placebo. However, orthogonalized measures of power coupling and phase coupling did not show the same effect of dexamphetamine as power-power coupling. We discuss the alterations of low- and high-frequency EEG power in response to dexamphetamine within the context of disorders of dopamine regulation, in particular schizophrenia, as well as in the context of a recently hypothesized association between low-frequency power and aspects of anhedonia. Hum Brain Mapp 37:570–588, 2016.

    U2 - 10.1002/hbm.23052

    DO - 10.1002/hbm.23052

    M3 - Article

    VL - 37

    SP - 570

    EP - 588

    JO - Human Brain Mapping

    JF - Human Brain Mapping

    SN - 1065-9471

    IS - 2

    ER -